On Thursday, in the course of current trade, Shares of Marathon Oil Corporation (NYSE:MRO), climbed 0.69%, and is now trading at $21.91.
Marathon Oil Corporation, declared that the Company’s board of directors has declared a quarterly dividend of 21 cents per share on the Company’s common stock. The dividend is payable on Sept. 10, 2015, to stockholders of record on Aug. 19, 2015.
Marathon Oil Corporation operates as an energy company. It operates in three segments: North America Exploration and Production, International Exploration and Production, and Oil Sands Mining.
During an Afternoon trade, Shares of Marathon Petroleum Corp (NYSE:MPC), dipped -3.57%, and is now trading at $53.81.
Cardtronics, declared it has reached a new, long-term agreement with Speedway LLC, the nation’s second largest company-owned and -operated convenience store chain. Cardtronics is the world’s largest retail ATM owner / operator.
The renewal agreement covers a footprint of about 2,750 stores located in 22 Midwest, East Coast and Southeast states. Cardtronics also has expansion rights to operate ATMs for Speedway in its future store locations.
David Dove, president, North American Business Group, Cardtronics, said:
“Cardtronics’ renewal with Speedway is in fact two renewals wrapped into one. At the end of 2014, Speedway closed its acquisition of Hess’ convenience store operations, a longtime Cardtronics client. With this renewal agreement we’ve secured our existing business and are poised to activate value-added traffic driving and traffic-to-buyer conversion tools for the benefit of our client and their customers.”
Marathon Petroleum Corporation, together with its auxiliaries, engages in refining, marketing, retailing, and transporting petroleum products primarily in the United States. It operates through three segments: Refining & Marketing, Speedway, and Pipeline Transportation.
Finally, RXi Pharmaceuticals Corp (NASDAQ:RXII), lost -2.44% on Thursday.
RXi Pharmaceuticals Corporation, declared that it will report financial results for the second quarter ended June 30, 2015 on Wednesday, August 12, 2015 after the close of the U.S. financial markets.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
